尿激酶型纤溶酶原激活剂（ｕＰＡ）是近年来研究较多的溶血栓药物之一。它存在两种形式：单链尿激酶（ｓｃｕＰＡ）或称尿激酶原及双链尿激酶（ｕＰＡ）或称尿激酶〔１〕。由于临床发现ｕＰＡ大剂量注射易出现大面积出血的倾向，所以，人们对特异性强于ｕＰＡ的ｓｃｕＰＡ进 Urokinase-type plasminogen activator (uPA) is one of the more studied thrombolytic drugs in recent years. It exists in two forms: single-chain urokinase (scuPA) or urokinase and double-chain urokinase (uPA) or urokinase [1]. As the clinical findings of large doses of uPA prone to massive bleeding tendency, so people are more specific than uP  A scuPA into